Cargando…

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis

BACKGROUND: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. OBJECTIVE: To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Madhurima, Koel-Simmelink, Marleen JA, Verberk, Inge MW, Killestein, Joep, Vrenken, Hugo, Enzinger, Christian, Ropele, Stefan, Fazekas, Franz, Khalil, Michael, Teunissen, Charlotte E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305953/
https://www.ncbi.nlm.nih.gov/pubmed/30627437
http://dx.doi.org/10.1177/2055217318819535
_version_ 1783382683460567040
author Chatterjee, Madhurima
Koel-Simmelink, Marleen JA
Verberk, Inge MW
Killestein, Joep
Vrenken, Hugo
Enzinger, Christian
Ropele, Stefan
Fazekas, Franz
Khalil, Michael
Teunissen, Charlotte E
author_facet Chatterjee, Madhurima
Koel-Simmelink, Marleen JA
Verberk, Inge MW
Killestein, Joep
Vrenken, Hugo
Enzinger, Christian
Ropele, Stefan
Fazekas, Franz
Khalil, Michael
Teunissen, Charlotte E
author_sort Chatterjee, Madhurima
collection PubMed
description BACKGROUND: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. OBJECTIVE: To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. METHODS: Cerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing–remitting multiple sclerosis (n = 41), secondary progressive multiple sclerosis (n = 26) and primary progressive multiple sclerosis patients (n = 13) and controls (n = 18), and in a second cohort with clinically isolated syndrome patients (n = 88, median clinical follow-up period of 2.3 years) and controls (n = 20). Correlations/linear regressions were analysed with other baseline cerebrospinal fluid axonal damage markers and cross-sectional/longitudinal magnetic resonance imaging features. RESULTS: Contactin-1 and contactin-2 levels were up to 1.4-fold reduced in relapsing–remitting multiple sclerosis (contactin-1: p = 0.01, contactin-2: p = 0.02) and secondary progressive multiple sclerosis (contactin-1: p = 0.05, contactin-2: p = 0.02) compared to controls. In clinically isolated syndrome patients, contactin-1 tended to increase when compared to controls (p = 0.07). Both contactin-1 and contactin-2 correlated with neurofilament light, neurofilament heavy and magnetic resonance imaging metrics differently depending on the disease stage. In clinically isolated syndrome patients, baseline contactin-2 level (β = –0.42, p = 0.04) predicted the longitudinal decline in cortex volume. CONCLUSION: Cerebrospinal fluid contactin-1 and contactin-2 reveal axonal dysfunction in various stages of multiple sclerosis and their inclusion to the biomarker panel may provide better insight into the extent of axonal damage/dysfunction.
format Online
Article
Text
id pubmed-6305953
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63059532019-01-09 Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis Chatterjee, Madhurima Koel-Simmelink, Marleen JA Verberk, Inge MW Killestein, Joep Vrenken, Hugo Enzinger, Christian Ropele, Stefan Fazekas, Franz Khalil, Michael Teunissen, Charlotte E Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. OBJECTIVE: To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. METHODS: Cerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing–remitting multiple sclerosis (n = 41), secondary progressive multiple sclerosis (n = 26) and primary progressive multiple sclerosis patients (n = 13) and controls (n = 18), and in a second cohort with clinically isolated syndrome patients (n = 88, median clinical follow-up period of 2.3 years) and controls (n = 20). Correlations/linear regressions were analysed with other baseline cerebrospinal fluid axonal damage markers and cross-sectional/longitudinal magnetic resonance imaging features. RESULTS: Contactin-1 and contactin-2 levels were up to 1.4-fold reduced in relapsing–remitting multiple sclerosis (contactin-1: p = 0.01, contactin-2: p = 0.02) and secondary progressive multiple sclerosis (contactin-1: p = 0.05, contactin-2: p = 0.02) compared to controls. In clinically isolated syndrome patients, contactin-1 tended to increase when compared to controls (p = 0.07). Both contactin-1 and contactin-2 correlated with neurofilament light, neurofilament heavy and magnetic resonance imaging metrics differently depending on the disease stage. In clinically isolated syndrome patients, baseline contactin-2 level (β = –0.42, p = 0.04) predicted the longitudinal decline in cortex volume. CONCLUSION: Cerebrospinal fluid contactin-1 and contactin-2 reveal axonal dysfunction in various stages of multiple sclerosis and their inclusion to the biomarker panel may provide better insight into the extent of axonal damage/dysfunction. SAGE Publications 2018-12-24 /pmc/articles/PMC6305953/ /pubmed/30627437 http://dx.doi.org/10.1177/2055217318819535 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Chatterjee, Madhurima
Koel-Simmelink, Marleen JA
Verberk, Inge MW
Killestein, Joep
Vrenken, Hugo
Enzinger, Christian
Ropele, Stefan
Fazekas, Franz
Khalil, Michael
Teunissen, Charlotte E
Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title_full Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title_fullStr Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title_full_unstemmed Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title_short Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
title_sort contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305953/
https://www.ncbi.nlm.nih.gov/pubmed/30627437
http://dx.doi.org/10.1177/2055217318819535
work_keys_str_mv AT chatterjeemadhurima contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT koelsimmelinkmarleenja contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT verberkingemw contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT killesteinjoep contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT vrenkenhugo contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT enzingerchristian contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT ropelestefan contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT fazekasfranz contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT khalilmichael contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis
AT teunissencharlottee contactin1andcontactin2incerebrospinalfluidaspotentialbiomarkersforaxonaldomaindysfunctioninmultiplesclerosis